residences [40:65 years of age does not appear to differ from that in younger adults; however, use with caution due to greater frequency of decreased hepatic, renal, and/or cardiac function and of concomitant disease and drug therapy observed in the elderly. a Hepatic Impairment Pharmacokinetics not evaluated; dosage adjustments may be required in patients with hyperbilirubinemia. a (See Hepatic Impairment under Dosage and Administration.) Renal Impairment Decreased clearance; dosage adjustments necessary in patients with moderate to severe renal impairment (Cl cr] FEATURED: CAR-T Cell Therapy Overview Mechanism of Action KTE-C19 Studies KTE-C19 Cancer Targets Adverse Events Manufacturing Drug Status Rx Availability Prescription only D Pregnancy Category Positive evidence of risk N/A CSA Schedule Not a controlled drug Approval History Drug history at FDA Manufacturer Mylan Pharmaceuticals Inc. Drug Class Miscellaneous uncategorized agents Related Drugs Cardiomyopathy Prophylaxis dexrazoxane , Zinecard , More... Extravasation hyaluronidase , dexrazoxane , Amphadase , Hylenex , Totect , Vitrase , More... Dexrazoxane Rating No Reviews - Be the first! No Reviews - Be the first! Not Rated - Be the first! charge
let you Dexrazoxane Hydrochloride deliberating
EmoticonEmoticon